

# Epimic Epidemiology Series: Fragile X Syndrome Forecast in 11 Major Markets 2016-2026

<https://marketpublishers.com/r/EB9389DA705EN.html>

Date: October 2016

Pages: 44

Price: US\$ 6,150.00 (Single User License)

ID: EB9389DA705EN

## Abstracts

Fragile X syndrome (FXS) is an X-linked dominant genetic disorder. It is caused by a defect in the fragile-X mental retardation 1 gene (FRM1); this defect prevents the FRM1 gene from expressing FMRP. The FMRP protein, most commonly found in the brain, is essential for normal cognitive development and female reproductive function. FXS is the leading genetically inherited cause of intellectual and developmental disability.

This report provides the current prevalent population for Fragile X Syndrome across 11 Major Markets (USA, France, Germany, Italy, Spain, UK, Australia, Japan, Brazil, India and China) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of Fragile-X have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Features associated with Fragile X Syndrome include:

Autistic-like features

Fragile X tremor ataxia syndrome (FXTAS)

Fragile X primary ovarian insufficiency (FXPOI)

Attention problems

Anxiety

Hyperactivity

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

Able to quantify patient populations in the global Fragile X Syndrome market to target the development of future products, pricing strategies and launch plans.

Gain further insight into the prevalence of the subdivided types of Fragile X Syndrome and identify patient segments with high potential.

Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.

Provide a level of understanding on the impact from specific co-morbid conditions on Fragile X Syndrome's prevalent population.

Identify sub-populations within Fragile-x which require treatment.

Gain an understanding of the specific markets that have the largest number of Fragile-x patients.

## Contents

- List of Tables and Figures
- Introduction
- Cause of the Disease
- Risk Factors & Prevention
- Diagnosis of the Disease
- Variation by Geography/Ethnicity
- Disease Prognosis & Clinical Course
- Key comorbid conditions/Features associated with the disease
- Methodology for quantification of patient numbers
  - Impact of HPV vaccination
  - Additional data available on request
- Top-line prevalence for Cervical Cancer
- Stage of Cervical Cancer patients
- Histopathology of Cervical Cancer patients
- Abbreviations used in the report
- Other Black Swan Analysis Publications
- Black Swan Analysis Online Patient-Based Databases
- Patient-Based Offering
- Online Pricing Data and Platforms
- References
- Appendix

## List Of Tables

### LIST OF TABLES

HPV type and disease association with cervical cancer  
HPV vaccines currently available  
The Bethesda Classification System for cervical squamous cell dysplasia  
FIGO staging of cervical cancer  
5-year survival rate by stage of cervical cancer  
Incidence of Cervical cancer, females (000s)  
Cervical cancer patients by FIGO stage, females (000s)  
Cervical cancer patients by histopathologic type, females (000s)  
Abbreviations and Acronyms used in the report  
USA Incidence of Cervical Cancer by 5-yr age cohort, females (000s)  
Canada Incidence of Cervical Cancer by 5-yr age cohort, females (000s)  
France Incidence of Cervical Cancer by 5-yr age cohort, females (000s)  
Germany Incidence of Cervical Cancer by 5-yr age cohort, females (000s)  
Italy Incidence of Cervical Cancer by 5-yr age cohort, females (000s)  
Spain Incidence of Cervical Cancer by 5-yr age cohort, females (000s)  
United Kingdom Incidence of Cervical Cancer by 5-yr age cohort, females (000s)  
Netherlands Incidence of Cervical Cancer by 5-yr age cohort, females (000s)  
Poland Incidence of Cervical Cancer by 5-yr age cohort, females (000s)  
Romania Incidence of Cervical Cancer by 5-yr age cohort, females (000s)  
Russia Incidence of Cervical Cancer by 5-yr age cohort, females (000s)  
Turkey Incidence of Cervical Cancer by 5-yr age cohort, females (000s)  
Australia Incidence of Cervical Cancer by 5-yr age cohort, females (000s)  
Japan Incidence of Cervical Cancer by 5-yr age cohort, females (000s)  
South Korea Incidence of Cervical Cancer by 5-yr age cohort, females (000s)  
China Incidence of Cervical Cancer by 5-yr age cohort, females (000s)  
India Incidence of Cervical Cancer by 5-yr age cohort, females (000s)  
Argentina Incidence of Cervical Cancer by 5-yr age cohort, females (000s)  
Brazil Incidence of Cervical Cancer by 5-yr age cohort, females (000s)  
Mexico Incidence of Cervical Cancer by 5-yr age cohort, females (000s)  
South Africa Incidence of Cervical Cancer by 5-yr age cohort, females (000s)  
Saudi Arabia Incidence of Cervical Cancer by 5-yr age cohort, females (000s)

## List Of Figures

### LIST OF FIGURES

Profiles of Cervical cancer incidence by age

Incidence of Cervical cancer by country

Expected impact in Cervical cancer incidence due to HPV immunisation (UK)

## I would like to order

Product name: Epiomic Epidemiology Series: Fragile X Syndrome Forecast in 11 Major Markets  
2016-2026

Product link: <https://marketpublishers.com/r/EB9389DA705EN.html>

Price: US\$ 6,150.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer  
Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click  
button on product page <https://marketpublishers.com/r/EB9389DA705EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form  
below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms  
& Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below  
and fax the completed form to +44 20 7900 3970

